To include your compound in the COVID-19 Resource Center, submit it here.

Inactine: VITX will begin in 3Q02 a double-blind U.S. Phase III study of Inactine in 70 patients requiring chronic red blood cell transfusion support

V.I. Technologies Inc. (VITX), Watertown, Mass.
Business: Blood

Read the full 80 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE